DN
Dianthus Therapeutics, Inc.
DNTH · NASDAQ
$96.81 -4.26% (-$4.31)
1M -7.66%
Market Cap $5.66B
P/E Ratio -
Div. Yield -
ROE 3.51%
Bulios Fair Price
$90.42
6.6% downside
Current Price
$96.81
Undervalued Fair Value Overvalued
According to Bulios Fair Price, DNTH is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
20 /100
Expensive P/S 2,970.63x
P/B 4.83x
P/E N/A
Growth
22 /100
Declining Rev. growth 31.80%
Book val. growth 88.51%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 96.01%
FCF margin 8,177.99%
Net margin 1,570.85%
Quality
0 /100
Poor ROIC 18.47%
Asset turnover 0.00x
ROE 3.51%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 26.10x
Int. coverage N/A
Stability
5 /100
Unstable Beta 0.08x
Profitable years 0
Rev. volatility 105.40%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about DNTH
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Marino Garcia
Employees
92
Headquarters
New York
Upcoming events
05 NOV
Earnings
Upcoming earnings report